MetaCap

Editas Medicine (EDIT) vs Fennec Pharmaceuticals (FENC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Over five years, FENC leads with a +12.7% price change compared with -92.8% for EDIT. Editas Medicine is the larger company by market cap ($422.3 million vs $363.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT-92.28%FENC+11.64%
+40%-32%-104%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus FENC key metrics
MetricEDITFENC
Share price$2.75$10.36
Market cap$422.35M$363.30M
1-day change+0.73%+0.10%
YTD return—+34.55%
1-year return—+9.28%
5-year return-92.77%+12.73%
Forward P/E—10.93
EPS (TTM)$-0.68$-0.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$4.54$13.25
52-week low$1.66$5.65
Distance from 52-week high-39.39%-21.81%
Average volume2.48M193.70K
Shares outstanding153.58M35.07M
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

EDIT vs FENC FAQ

Which is bigger, Editas Medicine or Fennec Pharmaceuticals?

Editas Medicine (EDIT) is larger, with a market capitalization of $422.35M compared with $363.30M for Fennec Pharmaceuticals (FENC).

Are Editas Medicine and Fennec Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons